Zevra Therapeutics Media Release | August 2, 2024

FDA Advisory Committee Votes Favourably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Read Zevra's Media Release Here

Read the letter from Zevra Therapeutics here:

Letter to NPC COmmunity Zevra Ad Com Results.pdf

Download PDF • 117KB

Here is a summary of the article:

• FDA Advisory Committee Vote: The U.S. FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favourably (11 yes, 5 no) that Arimoclomol is effective in treating patients with NPC.

• Clinical Data Support: The committee considered clinical data from pivotal trials, long-term open-label extension studies, and expanded access programs.

• About NPC: NPC is an ultra-rare, progressive, neurodegenerative lysosomal storage disorder caused by mutations in NPC1 or NPC2 genes.

• Arimoclomol: Zevra’s investigational drug candidate for NPC has received Orphan Drug designation and other regulatory designations (2). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 21, 2024 (3,4).

---

To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."

Ways to support NP-C in Australia:

• Donate online

• Check out upcoming events

• Shop at our online NPC store

• Fundraise your way! Check our free resources and inspo online.